Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia

NCT03009240 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03009240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2017
Completion date
March 19, 2026
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, recurrent acute myeloid leukemia, refractory acute myeloid leukemia, secondary acute myeloid leukemia, therapy-related acute myeloid leukemia, untreated adult acute myeloid leukemia